Delivery Order SPE2DB24D2012-SPE2DB25FBWGT
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,339.52 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packages) on August 21, 2025, with an ultimate completion date of August 22, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $14,532.44 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit dose packaging) on November 26, 2025, with completion scheduled for November 28, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply services to federal medical procurement needs. The order will be fulfilled from AmerisourceBergen's Corporate Office location in...
- The Defense Logistics Agency awarded a delivery order valued at $6,840.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 24, 2025, with completion targeted for November 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its Corporate Office location in...
- The Defense Logistics Agency awarded a delivery order valued at $58,100.78 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on May 5, 2025, with an ultimate completion date of May 6, 2025. This firm fixed price, non-set-aside delivery order represents a purchase of pharmaceutical inventory to support federal medical procurement needs. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $11.84K to AmerisourceBergen Drug Corp on May 5, 2025, for the supply of RINVOQ ER 15 MG tablets (30-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by May 6, 2025, with performance at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting AmerisourceBergen's qualification to compete in open federal...
- The Defense Logistics Agency awarded a delivery order valued at $15,679.59 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency awarded a $25,342.86 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) with an ultimate completion date of July 29, 2025. This competitively awarded, non-set-aside contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply relationship with the federal government. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $12,446.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-set-aside contract represents a small-value pharmaceutical procurement fulfilling federal medical supply requirements. The award was made to AmerisourceBergen's Corporate Office division, located in Conshohocken, Pennsylvania, which serves as the company's primary...
- The Defense Logistics Agency awarded a delivery order valued at $5,031.82 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-set-aside, firm fixed-price delivery order was competitively awarded and represents a continuation of the vendor's pharmaceutical supply support to federal healthcare systems. The contract performance location is AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $13,565.47 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under a larger indefinite delivery contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken,...
- SPE2DB24D2012Indefinite Delivery Contract
- SPE2DB24D2012-SPE2DB25FBWGTDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $12,478.85 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on June 24, 2025, with completion scheduled for June 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's comprehensive Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle through December 2026 that serves as a global pharmaceutical support mechanism for military healthcare systems worldwide. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, supplies an extensive range of medications, vaccines, medical devices, and healthcare commodities to support Defense Health Agency operations and other federal healthcare systems. The company's federal contract portfolio demonstrates consistent competitively awarded delivery orders with firm fixed pricing across multiple therapeutic domains, positioning it as a critical vendor in the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.5k | 6/24/25 |